Since no IND was filed, we can assume the Phase I for CX1739 is being run overseas, where the regulatory runaround for Phase I is much less--and trials can often be done more cheaply. Having good offshore Phase I data can then make it easier to get the US IND approved.
In terms of the GSK schizophrenia program, I don't recall offhand when the cognition use patent expires, but off-the-top-of-my-head, I'd guess 2014. I could look through my Cortex file, but it's early.
Entering PhI in mid-2008, a successful schizophrenia development program and NDA would not lead to commercialization before 2014, thus the use patent doesn't matter nearly as much as it once seemed to. But as Spyderboi noted, there may be problems with the compound itself--to me, using a high-impact in schizophrenia is like sticking a Porsche engine in a dune buggy.
NeuroInvestment
Market Data 
Markets 
AI
